Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gene Logic Signs Two New Partners

September 3, 2007 | A version of this story appeared in Volume 85, Issue 36

Gene Logic has snared two new customers for its drug repositioning program, which explores new applications for drug candidates that were safe but ineffective in clinical trials. In separate deals, Merck Serono and Solvay Pharmaceuticals have enlisted the Gaithersburg, Md.-based biotech to look for new uses for drug candidates. In each pact, Gene Logic will receive milestone and royalty payments on compounds that are put back in the clinic; it has the option to license any drug that the companies do not elect to pursue.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.